Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics

Introduction Maintenance therapy with bevacizumab and the poly (ADP-ribose) polymerases (PARP) inhibitors olaparib and niraparib after first-line treatment of advanced ovarian cancer has been approved. However, it is not clear which one should be used for which patients.